OptimizeRx Croissance future
Future contrôle des critères 1/6
OptimizeRx is forecast to grow earnings and revenue by 29.1% and 19.4% per annum respectively while EPS is expected to grow by 32.2% per annum.
Informations clés
29.1%
Taux de croissance des bénéfices
32.2%
Taux de croissance du BPA
| Healthcare Services croissance des bénéfices | 30.6% |
| Taux de croissance des recettes | 19.4% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 10 Sep 2024 |
Mises à jour récentes de la croissance future
Recent updates
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
Jul 30
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
Jan 09Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)
Aug 24OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely
Aug 16Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?
May 31OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio
Oct 12Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?
Sep 23OptimizeRx extends reach with Cooler Screens Partnership
Jul 26OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
Jun 27The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business
Nov 16Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All
Aug 13A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)
Jul 15Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation
Jun 24Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist
May 10Estimating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)
Mar 29Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2025 | 114 | -11 | N/A | N/A | 7 |
| 12/31/2024 | 101 | -12 | N/A | N/A | 7 |
| 6/30/2024 | 83 | -18 | -2 | -2 | N/A |
| 3/31/2024 | 78 | -18 | -6 | -5 | N/A |
| 12/31/2023 | 72 | -18 | -8 | -7 | N/A |
| 9/30/2023 | 63 | -14 | 0 | 2 | N/A |
| 6/30/2023 | 62 | -14 | 2 | 4 | N/A |
| 3/31/2023 | 62 | -14 | 6 | 6 | N/A |
| 12/31/2022 | 62 | -11 | 10 | 11 | N/A |
| 9/30/2022 | 63 | -10 | 6 | 7 | N/A |
| 6/30/2022 | 64 | -7 | 3 | 3 | N/A |
| 3/31/2022 | 64 | -3 | 3 | 3 | N/A |
| 12/31/2021 | 61 | 0 | 0 | 1 | N/A |
| 9/30/2021 | 57 | 1 | -1 | -1 | N/A |
| 6/30/2021 | 52 | 1 | -1 | -1 | N/A |
| 3/31/2021 | 47 | -1 | -1 | -1 | N/A |
| 12/31/2020 | 43 | -2 | -6 | -6 | N/A |
| 9/30/2020 | 34 | -6 | -6 | -5 | N/A |
| 6/30/2020 | 29 | -7 | -7 | -6 | N/A |
| 3/31/2020 | 27 | -5 | -8 | -6 | N/A |
| 12/31/2019 | 25 | -3 | -3 | -2 | N/A |
| 9/30/2019 | 24 | -1 | 0 | 1 | N/A |
| 6/30/2019 | 24 | 1 | 2 | 3 | N/A |
| 3/31/2019 | 22 | 0 | 2 | 2 | N/A |
| 12/31/2018 | 21 | 0 | 1 | 1 | N/A |
| 9/30/2018 | 19 | 0 | 0 | 0 | N/A |
| 6/30/2018 | 16 | -1 | -2 | -2 | N/A |
| 3/31/2018 | 14 | -1 | N/A | -2 | N/A |
| 12/31/2017 | 12 | -2 | N/A | -1 | N/A |
| 9/30/2017 | 10 | -2 | N/A | -2 | N/A |
| 6/30/2017 | 9 | -2 | N/A | -1 | N/A |
| 3/31/2017 | 8 | -2 | N/A | 0 | N/A |
| 12/31/2016 | 8 | -2 | N/A | 0 | N/A |
| 9/30/2016 | 7 | -2 | N/A | 0 | N/A |
| 6/30/2016 | 8 | -1 | N/A | 0 | N/A |
| 3/31/2016 | 7 | -1 | N/A | 0 | N/A |
| 12/31/2015 | 7 | -1 | N/A | 1 | N/A |
| 9/30/2015 | 7 | 0 | N/A | 1 | N/A |
| 6/30/2015 | 7 | 0 | N/A | 0 | N/A |
| 3/31/2015 | 7 | 0 | N/A | 0 | N/A |
| 12/31/2014 | 7 | -1 | N/A | 0 | N/A |
| 9/30/2014 | 6 | -1 | N/A | 1 | N/A |
| 6/30/2014 | 6 | -1 | N/A | 1 | N/A |
| 3/31/2014 | 5 | -1 | N/A | 1 | N/A |
| 12/31/2013 | 5 | 0 | N/A | 1 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: OPRX is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: OPRX is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: OPRX is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: OPRX's revenue (19.4% per year) is forecast to grow faster than the US market (8.9% per year).
Croissance élevée des revenus: OPRX's revenue (19.4% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if OPRX's Return on Equity is forecast to be high in 3 years time